Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy
Completed
- Conditions
- Bleeding
- Interventions
- Drug: Antithrombotics
- Registration Number
- NCT00625248
- Lead Sponsor
- Pain Management Center of Paducah
- Brief Summary
This study will evaluate bleeding risk and differences in outcomes in patients receiving and not receiving anticoagulant or antiplatelet therapy
- Detailed Description
1. To evaluate bleeding risk in interventional procedures in patients with or without antiplatelet and/or anticoagulant therapy.
2. To evaluate differences in outcomes in patients not receiving any anticoagulant or antiplatelet therapy compared to patients receiving various types of drugs with anticoagulant or antiplatelet therapeutic effects.
3. To evaluate and compare the adverse event profiling all patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12000
Inclusion Criteria
- Subjects undergoing interventional techniques. Subjects who were able to give voluntary, written informed consent.
Exclusion Criteria
- All those things, patients on heparin, dextran, and low molecular heparin
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description no anthithrombotic Antithrombotics procedures where there were no antithrombotics Antithrombotic - continued Antithrombotics patients who are on antithrombotics Discontinued Antithrombotic Antithrombotics Patients who were on antithrombotics but have been discontinued
- Primary Outcome Measures
Name Time Method To evaluate for differences between the patients undergoing interventional techniques with or without anticoagulant or antiplatelet therapy. 24 months
- Secondary Outcome Measures
Name Time Method To assess adverse events in all patients. 24 months
Trial Locations
- Locations (1)
Pain Management Center of Paducah
🇺🇸Paducah, Kentucky, United States